2021, Clinical Trials, Conditions and Media

MyMD Pharmaceuticals Subsidiary Oravax Medical Preparing to Commence Clinical Trials for Oral COVID-19 Vaccine

Cannabis Law Report

AUGUST 10, 2021

(Nasdaq: MYMD) (“MyMD” or “the Company”), a clinical stage pharmaceutical company committed to extending healthy lifespan by focusing on developing two therapeutic platforms, today reported that its subsidiary Oravax Medical Inc. Oravax was established in March 2021 by Oramed Pharmaceuticals Inc. Media Contact: Will Johnson.

Clinical Trials

Clinical Trials Pharmaceutical Research and Development CBD

MyMD Pharmaceuticals Announces Fourth Quarter 2021 Initiation of Phase 2 Clinical Trial of MYMD-1 for Extending Healthy Lifespan

Cannabis Law Report

SEPTEMBER 13, 2021

(Nasdaq: MYMD) (“MyMD” or “the Company”), a clinical stage pharmaceutical company committed to extending healthy lifespan, today announced that it intends to initiate dosing for a Phase 2 trial of MYMD-1’s function in delaying aging early in the fourth quarter of 2021. 3 Nature Aging | VOL 1 | July 2021 | p.

Clinical Trials

Clinical Trials Pharmaceutical Research and Development Therapy

CBD Market Report

Project CBD

FEBRUARY 28, 2023

HerbalGram, the acclaimed quarterly journal of the American Botanical Council, recently published its 2021 “Herb Market Report,” which included data on sales of CBD as an herbal ingredient in mainstream and natural retail channels in the United States. in 2021 reached $2 billion, according to Statistica.) 2 The seeds of C.

CBD

CBD Seed-To-Sale Food Access

TGA – Australia: Independent Expert Panel on MDMA and psilocybin – Systematic literature review of the therapeutic value, benefits and risks of MDMA and psilocybin for the treatment of mental health conditions

Cannabis Law Report

OCTOBER 5, 2021

Systematic literature review of the therapeutic value, benefits and risks of MDMA and psilocybin for the treatment of mental health conditions. 30 September 2021. On 5 August 2021, the TGA announced that an Independent Expert Panel had been established to undertake the review. The review excludes pre-clinical trials (i.e.

Treatment

Treatment Conditions Medicine Clinical Trials

IGC Reports Financial Results for the September 30, 2021 Quarter

Cannabis Law Report

OCTOBER 29, 2021

(NYSE American: IGC) announces its financial results for the three months ended September 30, 2021, which is the second quarter of the Company’s 2022 fiscal year. During the six months ended September 30, 2021, the Company raised approximately $4.1 million for the three months ended September 30, 2021, from approximately $1.48

Clinical Trials

Clinical Trials Research and Development Data Business

Gb Sciences Completes $8 Million Sale of Las Vegas Cannabis Facility

Cannabis Law Report

JANUARY 12, 2022

. “Gb Sciences has established a pipeline of patent-protected combination therapies for the treatment of medical conditions affecting hundreds of millions of people,” said Dr. Andrea Small-Howard, President and Chief Science Officer of Gb Sciences. Media Contact. In addition, Gb Sciences has 12 U.S. Savannah Muir.

Research and Development

Research and Development Clinical Trials Chronic Pain Therapy

Cybin Announces Closing of Overnight Marketed Public Offering of Common Shares and Exercise of Over-Allotment Option

Cannabis Law Report

AUGUST 3, 2021

The Shares were offered in each of the provinces of Canada, excluding Québec, pursuant to a prospectus supplement to the Company’s short form base shelf prospectus dated July 5, 2021. Vigorous scientific research and clinical trials are needed. Cybin has not conducted clinical trials for the use of its proposed products.

Clinical Trials

Clinical Trials Events Treatment Banking

Press Release: Small Pharma Granted Fast-Track Designation From U.K. Regulator for DMT-Assisted Therapy for Major Depressive Disorder

Cannabis Law Report

OCTOBER 22, 2021

21, 2021 (GLOBE NEWSWIRE) — Small Pharma Inc. SPL026 entered clinical trials at the beginning of 2021 and this designation marks an important step forward towards an accelerated drug approval pathway for bringing the benefits of SPL026 to market for patients suffering with MDD.”. Media Relations Contact.

Therapy

Therapy Clinical Trials Research and Development Treatment

MedXtractor Fills a Key Gap in Mental Health Treatments

Cannabis Law Report

JUNE 30, 2021

Yet, despite nearly two billion people with mental illness each year, these conditions are routinely misdiagnosed and inadequately treated. In addition, the company aims to predict what treatments are most effective in addressing these conditions, including psychedelics, which have shown tremendous promise in early clinical trials.

Treatment

Treatment Clinical Trials Research and Development Data

Press Release: Entheon Biomedical Announces EEG Patent Application & Provides Research Update

Cannabis Law Report

DECEMBER 26, 2021

December 17, 2021 ·. – December 16, 2021) – Entheon Biomedical Corp. 63/283,051, titled “Detection of Therapeutic Psychedelic State,” as of November 23, 2021. Further to the Corporate Update provided on November 24, 2021, the Company is pleased to announce further progress on its nonclinical program.

Research and Development

Research and Development Clinical Trials Treatment Packaging

MyMD Pharmaceuticals to Detail its Two Upcoming Phase 2 Trials at the Benzinga Rising Stars: Catalytic Small Cap Growth Conference on October 7

Cannabis Law Report

OCTOBER 5, 2021

(Nasdaq: MYMD) (“MyMD” or “the Company”), a clinical stage pharmaceutical company committed to extending healthy lifespan, today announced that it will present at the Benzinga Rising Stars: Catalytic Small Cap Growth Conference on Thursday, October 7, 2021. Media: media@mymd.com. ET on Benzinga’s live stream channel.

Pharmaceutical

Pharmaceutical Clinical Trials Chronic Pain Media

MyMD Pharmaceuticals Set to Join Russell Microcap® Index

Cannabis Law Report

JUNE 7, 2021

A discussion of these and other factors with respect to MyMD is set forth in the registration statement on Form S-4 filed by MyMD on January 15, 2021, as amended. Media Contact: Will Johnson. Investor Contact: Brett Maas. 646-536-7331. brett@haydenir.com www.haydenir.com. 201-465-8019.

Pharmaceutical

Pharmaceutical Clinical Trials CBD Banking

Radicle Science Announces XPRIZE Foundation and Singularity University Founder Peter H. Diamandis MD as Chair of Advisory Board

Cannabis Law Report

OCTOBER 12, 2021

SAN DIEGO–(BUSINESS WIRE)– #CBD — Radicle Science , a transformative healthtech B-corp validating consumer health products for the first time, secured its initial seed funding in Q4 2020 and surpassed numerous major milestones with accelerating momentum in the first three quarters of 2021. Notably, Peter H.

Clinical Trials

Clinical Trials Research and Development Sleep Cannabinoids

Former member of the National Advisory Council on Drug Abuse (NACDA) and National Institute on Drug Abuse (NIDA) Joins Ehave, Inc; Ehave Appoints Psychopharmacologist, Board-Certified Psychiatrist, And Licensed Physician, Bankole Johnson To Its Medical Advisory Board

Cannabis Law Report

JULY 6, 2021

July 06, 2021 08:30 ET | Source: Ehave. MIAMI, July 06, 2021 (GLOBE NEWSWIRE) — Ehave, Inc., (OTC A replay of the interview is available on the media section of the Company’s website at: [link]. Dr. Bankole Johnson was featured in a March 5 th 2021 Forbes article, “Dr. ” About Ehave, Inc. Ehave, Inc.

Research and Development

Research and Development Wellness and Beauty Clinical Trials Therapy

MyMD Pharmaceuticals Announces New Data Demonstrating 8,000 Times Higher Potency of Novel Synthetic Supera-CBD over Plant-Derived CBD

Cannabis Law Report

SEPTEMBER 22, 2021

At 8,000 times the potency of regular CBD, we believe that Supera-CBD shows strong potential as a therapeutic for high-threat diseases and conditions like Alzheimer’s, psychosis, neuropathic pain, addiction, and anxiety. Supera-CBD is currently on a path toward human clinical trials as a therapy for epilepsy, followed by chronic pain.

Pharmaceutical

Pharmaceutical Data CBD Clinical Trials

Delic to Acquire Ketamine Wellness Centers Inc, Becoming Largest Psychedelic Wellness Chain in United States

Cannabis Law Report

SEPTEMBER 20, 2021

Delic expects to open 15 additional clinics across the country over the coming 18 months, further expanding access to millions who can benefit from psychedelic treatment for a variety of mental health conditions. Transaction Highlights.

Treatment

Treatment Media Research and Development Patients

MyMD Pharmaceuticals Announces New Data from Comparative Study on Lead Compound MYMD-1

Cannabis Law Report

JULY 7, 2021

A discussion of these and other factors with respect to MyMD is set forth in the Quarterly Report on Form 10-Q for the quarterly period ended March 31, 2021, filed by MyMD on May 18, 2021. Media Contact: Will Johnson. Investor Contact: Robert Schatz. 646) 421-9523. rschatz@mymd.com www.mymd.com. 201-465-8019.

Pharmaceutical

Pharmaceutical Data Clinical Trials Research and Development

Atai Life Sciences N.V. Added to the North American Psychedelics Index

Cannabis Law Report

JULY 9, 2021

The Horizons ETFs product family includes a broadly diversified range of solutions for investors of all experience levels to meet their investment objectives in a variety of market conditions. Horizons ETFs has over $19 billion of assets under management and 95 ETFs listed on major Canadian stock exchanges. Related Links.

Data

Data Clinical Trials Decriminalization Hemp

South Australia: Is Adelaide About To See A Medical Cannabis Boom?

Cannabis Law Report

SEPTEMBER 1, 2019

The Victorian and New South Wales Governments had both begun clinical trials of cannabis products for children with severe epilepsy and for palliative care, respectively. Minister for Industry and Skills David Pisoni published a media release to mark the occasion, entitled South Australia welcomes cannabis industry leaders.

Clinical Trials

Clinical Trials Research and Development Medicine Cultivation

Paper: The transition of cannabis into the mainstream of Australian healthcare: framings in professional medical publications

Cannabis Law Report

NOVEMBER 24, 2021

Medicinal cannabis has been legalised for use for a range of specified medical conditions in Australia since 2016. Media representations can offer insights into the nature of the discourse about new medical products and therapies and how ideas and understandings about social phenomena become constructed. Conclusions. Background.

Research and Development

Research and Development Medicine Access Media

Can cannabis prevent or treat coronavirus?

Alchimia

JANUARY 25, 2022

At the beginning of this new year of 2022, a news story about how cannabis can help fight COVID-19 was picked up by many non-cannabis media. While this research is certainly worth celebrating, the reality behind the message can be easily misunderstood in this age of social media.

Research and Development

Research and Development Terpenes CBD Treatment

Psychedelic Invest’s 100 Most Influential People in Psychedelics List

Cannabis Law Report

JUNE 4, 2021

This list is focused on those who have had the largest impact for 2021. . Our proprietary ranking system takes into account: Social reach (social media, blogs, podcasts, publications, etc.). Through his social media outlets, podcast, blog, and interviews, Tim has educated hundreds of millions of people about psychedelics.

Research and Development

Research and Development Medicine Treatment Pharmaceutical

Psychedelic Science Leader Eleusis to Become Public Company in Merger with Silver Spike Acquisition Corp. II

Cannabis Law Report

JANUARY 20, 2022

ELE-Psilo program expected to enter clinical trials in Q2 2022 and to target the pressing need for rapid-acting antidepressants compatible with existing healthcare infrastructure and insurance. Media and Investor Contacts For Eleusis: Alex Speiser, Corporate Development Director. Email: alexander.speiser@eleusisltd.com.

Therapy

Therapy Research and Development Business Access

Medical Cannabis Brief

MyMD Pharmaceuticals Subsidiary Oravax Medical Preparing to Commence Clinical Trials for Oral COVID-19 Vaccine

MyMD Pharmaceuticals Announces Fourth Quarter 2021 Initiation of Phase 2 Clinical Trial of MYMD-1 for Extending Healthy Lifespan

Trending Sources

CBD Market Report

TGA – Australia: Independent Expert Panel on MDMA and psilocybin – Systematic literature review of the therapeutic value, benefits and risks of MDMA and psilocybin for the treatment of mental health conditions

IGC Reports Financial Results for the September 30, 2021 Quarter

Gb Sciences Completes $8 Million Sale of Las Vegas Cannabis Facility

Cybin Announces Closing of Overnight Marketed Public Offering of Common Shares and Exercise of Over-Allotment Option

Press Release: Small Pharma Granted Fast-Track Designation From U.K. Regulator for DMT-Assisted Therapy for Major Depressive Disorder

MedXtractor Fills a Key Gap in Mental Health Treatments

Press Release: Entheon Biomedical Announces EEG Patent Application & Provides Research Update

MyMD Pharmaceuticals to Detail its Two Upcoming Phase 2 Trials at the Benzinga Rising Stars: Catalytic Small Cap Growth Conference on October 7

MyMD Pharmaceuticals Set to Join Russell Microcap® Index

Radicle Science Announces XPRIZE Foundation and Singularity University Founder Peter H. Diamandis MD as Chair of Advisory Board

Former member of the National Advisory Council on Drug Abuse (NACDA) and National Institute on Drug Abuse (NIDA) Joins Ehave, Inc; Ehave Appoints Psychopharmacologist, Board-Certified Psychiatrist, And Licensed Physician, Bankole Johnson To Its Medical Advisory Board

MyMD Pharmaceuticals Announces New Data Demonstrating 8,000 Times Higher Potency of Novel Synthetic Supera-CBD over Plant-Derived CBD

Delic to Acquire Ketamine Wellness Centers Inc, Becoming Largest Psychedelic Wellness Chain in United States

MyMD Pharmaceuticals Announces New Data from Comparative Study on Lead Compound MYMD-1

Atai Life Sciences N.V. Added to the North American Psychedelics Index

South Australia: Is Adelaide About To See A Medical Cannabis Boom?

Paper: The transition of cannabis into the mainstream of Australian healthcare: framings in professional medical publications

Can cannabis prevent or treat coronavirus?

Psychedelic Invest’s 100 Most Influential People in Psychedelics List

Psychedelic Science Leader Eleusis to Become Public Company in Merger with Silver Spike Acquisition Corp. II

Stay Connected